Financially-troubled Scotia hit by regulatory problems
This article was originally published in Clinica
Executive Summary
The continued survival of Scotia Holdings is in doubt after its key product, Foscan, a light-sensitive drug to treat advanced head and neck cancer tumours, unexpectedly failed to receive approval from the US FDA. Scotia, which now faces severe financial difficulties, is reviewing options for the company, which could include a merger, a disposal or fundraising. Shares in the UK company fell around 60% to 47.5p ($0.7) on the news, before plunging further to finish at just above 24p as Clinica went to press. This compares with a year-high of 230p in March.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.